Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A U.S. Registry of Eosinophilic Esophagitis Patients Treated With DUPIXENT® As Standard of Care

NCT06693531 is registered in ClinicalTrials.gov with Regeneron Pharmaceuticals as lead sponsor.

NCT NCT06693531
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06693531 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A U.S. Registry of Eosinophilic Esophagitis Patients Treated With DUPIXENT® As Standard of Care
Lead sponsor
Regeneron Pharmaceuticals
Phase
Observational
Overall status
Active, not recruiting
Start date
November 22, 2024
Completion date
May 22, 2030
Enrollment
368 (actual)
Sites
54

Conditions

As the registry lists them; a condition with its own page is linked.

eosinophilic esophagitis (eoe)